Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy.
Ana DevesaAndrea Camblor BlascoAna María Pello LázaroElham AskariGregoria LapeñaSandra Gómez TalaveraMikel Taibo UrquíaCelia Rodríguez-Olleros RodríguezJose TuñonBorja IbáñezÁlvaro AceñaPublished in: ESC heart failure (2021)
In a cohort of patients with HFpEF without LVH, the prevalence of TTR cardiac amyloidosis was 5%. Early diagnosis of cardiac involvement in TTR amyloidosis (before manifest LVH) would seem recommendable because newly approved specific treatments can prevent additional deposition of amyloid material.